■我们最近的研究表明,下丘脑中的脂氧合酶(LOX)和环氧合酶(COX)酶的表达被nesfatin-1激活,导致白三烯和前列腺素(PG)的释放,分别。此外,我们之前的报告解释说,脑室内(ICV)nesfatin-1治疗可引发中枢LOX和COX酶介导的心血管反应.在我们之前的报告基础上,本研究试图阐明心血管活性中枢COX产品的作用,如血栓烷(TX)A2,PGF2α,PGE,和PGD,在平均动脉压(MAP)和心率(HR)中协调nesfatin-1诱发的反应。
■SpragueDawley老鼠,在侧脑室有引导套管用于侧脑室(ICV)注射,在股动脉有导管用于监测MAP和HR,进行中央预处理与fureregrelate(TXA2合成酶抑制剂),PGF2α-二甲胺(PGF2α-DA,PGF2α受体拮抗剂),或AH6809(PGE和PGD受体拮抗剂),在ICVnesfatin-1施用前5分钟。观察并记录治疗后60分钟的心血管参数。
■Nesfatin-1诱导大鼠心血管反应,导致MAP的升压效应,和HR中的心动过缓后的心动过速。有趣的是,ICVfuregreales,PGF2α-DA,或AH6809预处理部分减轻了nesfatin-1揭示的心血管作用。
■这些发现阐明了nesfatin-1通过特异性TXA2,PGF2α的中枢激活在调节MAP和HR中的作用,PGE,和来自COX代谢物的PGD。此外,该研究还可能提示除这些COX代谢物外的其他中枢COX或LOX代谢物可能参与介导nesfatin-1产生的心血管作用.
UNASSIGNED: Our recent study revealed that the expression of lipoxygenase (LOX) and cyclooxygenase (COX) enzymes in the hypothalamus is activated by nesfatin-1, leading to the liberation of leukotrienes and prostaglandins (PG), respectively. Moreover, our prior report explained that intracerebroventricular (ICV) nesfatin-1 treatment triggers cardiovascular responses mediated by central LOX and COX enzymes. Building upon our prior reports, the present investigation sought to clarify the role of cardiovascularly active central COX products, such as thromboxane (TX) A2, PGF2α, PGE, and PGD, in orchestrating nesfatin-1-evoked reactions in mean arterial pressure (MAP) and heart rate (HR).
UNASSIGNED: The Sprague Dawley rats, which had guide cannula in the lateral ventricle for intracerebroventricular (ICV) injections and catheter in arteria femoralis for monitoring MAP and HR, were underwent central pretreatment with furegrelate (the TXA2 synthase inhibitor), PGF2α-dimethylamine (PGF2α-DA, the PGF2α receptor antagonist), or AH6809 (the PGE and PGD receptor antagonist), 5 min prior to ICV nesfatin-1 administration. The cardiovascular parameters were observed and recorded for 60 min posttreatment.
UNASSIGNED: Nesfatin-1 induced cardiovascular responses in rats leading to pressor effect in MAP, and tachycardia following bradycardia in HR. Interestingly, ICV furegrelate, PGF2α-DA, or AH6809 pretreatment partially mitigated the cardiovascular effects revealed by nesfatin-1.
UNASSIGNED: The findings illuminate the role of nesfatin-1 in modulating MAP and HR through the central activation of specifically TXA2, PGF2α, PGE, and PGD from COX metabolites. Additionally, the study may also suggest the potential involvement of other central COX or LOX metabolites beyond these COX metabolites in mediating the cardiovascular effects produced by nesfatin-1.